Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

Fineline Cube Jan 5, 2025

Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...

Company Drug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

Fineline Cube Jan 3, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...

Company Drug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...

Company Drug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

Fineline Cube Jan 3, 2025

US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...

Company Drug

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

Fineline Cube Jan 3, 2025

China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

Shanghai Enacts New Regulations for Drug and Medical Device Administration

Fineline Cube Jan 3, 2025

The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...

Company Drug

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Fineline Cube Jan 3, 2025

Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...

Company Deals

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

Fineline Cube Jan 3, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...

Company Drug

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

Fineline Cube Jan 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...

Company Drug

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Fineline Cube Jan 3, 2025

Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...

Company Drug

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Medical Device

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment

Fineline Cube Jan 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...

Company Drug

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

Fineline Cube Jan 3, 2025

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial

Fineline Cube Jan 3, 2025

Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...

Company Deals

Cygenta Partners with IZVARINO Pharma for Comprehensive CDMO Services

Fineline Cube Jan 3, 2025

Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based...

Company Deals

Pfizer Collaborates with Atavistik Bio to Discover Allosteric Therapeutics

Fineline Cube Jan 3, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm...

Company Drug

NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...

Company Medical Device

Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery

Fineline Cube Jan 2, 2025

Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from...

Company Drug

Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management

Fineline Cube Jan 2, 2025

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...

Company Deals

Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing

Fineline Cube Jan 2, 2025

Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...

Posts pagination

1 … 251 252 253 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.